Preview

Rational Pharmacotherapy in Cardiology

Advanced search

COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE

https://doi.org/10.20996/1819-6446-2013-9-4-398-403

Full Text:

Abstract

Aim. To compare direct medical costs of dabigatran and warfarin therapy in patients with non-valvular atrial fibrillation (NVAF) during preparation for elective cardioversion. Material and methods. An open non-randomized study was conducted to evaluate direct medical costs (cost of drug, cost of the international normalized ratio (INR) adjust- ment in outpatient clinic, cost of visits to cardiologist). Patients (n=62) with persistent NVAF (AF paroxysm duration > 48 hours) were enrolled. All of them requested medical as- sistance and were decided to perform an elective cardioversion. The patients received warfarin (n=32) or dabigatran (n=30). The patients of the both groups were similar in the main clinical characteristics and thromboembolic risk levels according to CHA2DS2-VASc scale.
Results. Treatment duration before elective cardioversion was 21±2 and 30.5±4.5 days for dabigatran and warfarin groups, respectively (p<0.05). Average costs of visits to cardiologists were 3,720 and 744 RUB in warfarin and dabigatran groups, respectively (p<0.05), and drug costs were 53.63 and 1,172.01 RUB, respectively (p<0.05). The costs of laboratory INR monitoring were 3,058 RUB in warfarin group. Total costs per patient were 6,831.63 and 1,916.01 RUB in warfarin and dabigatran groups, respectively (p<0.05). Conclusion. In the real clinical practice in patients with NVAF dabigatran antithromboembolic therapy substantially reduces direct medical costs in comparison with warfarin ther- apy during preparation for elective cardioversion. Dabigatran therapy reduces time from the decision of elective cardioversion and antithromboembolic therapy start to car- dioversion performance.

About the Authors

L. E. Kuvshinova
Saratov Research Institute of Cardiology, Saratov
Russian Federation


N. V. Furman
Saratov Research Institute of Cardiology, Saratov
Russian Federation


P. V. Dolotovskaya
Saratov Research Institute of Cardiology, Saratov
Russian Federation


Ya. P. Dovgalevsky
Saratov Research Institute of Cardiology, Saratov State Medical University named after V.I. Razumovsky, Saratov
Russian Federation


References

1. Benjamin E.J., Levy D., Vaziri S.M. et al. Independent risk factors for atrial fibrillation in a populationbased cohort. The Framingham Heart Study. JAMA 1994;271(11):840-4.

2. Stewart S., Hart C.L., Hole D.J., McMurray J.J. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002;113(5):359-64.

3. Kirchhof P., Bax J., Blomstrom-Lundquist C. et al Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation. Europace 2009;11(7):860-85.

4. Camm A.J., Kirchhof P., Lip G.Y. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360-1420.

5. Camm AG, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012; 33: 2719-47.

6. Wann L.S., Curtis A.B., Ellenbogen K.A. et al. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123(10):1144-5

7. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Fram-ngham Study. Stroke 1991;22:983-988

8. Hart R.G., Halperin J.L. Atrial fibrillation and stroke: concepts and controversies. Stroke 2001;32(3):803-8.

9. Wolowacz S.E., Samuel M., Brennan V.K. et al The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace 2011;13(10):1375-85.

10. Heemstra H.E., Nieuwlaat R., Meijboom M., Crijns H.J. The burden of atrial fibrillation in the Netherlands. Neth Heart J 2011;19(9):373-8.

11. Vorobiev P.A. The clinico-economic analysis in the medical organisation (practical guidance for the persons, making decisions). Standartizing Problems in Public Health Services 2004;(7):83-114. Russ- ian (Воробьев П.А. Клинико-экономический анализ в медицинской организации (практическое руководство для лиц, принимающих решения). Проблемы Стандартизации в Здравоохранении 2004;(7):83-114)

12. Rostova Н.Б., Soloninina А.В. About rational use of medicines. Public Health Services of the Russian Federation 2008; (3):42-44. Russian (Ростова Н.Б., Солонинина А.В. О рациональном использовании лекарственных средств. Здравоохранение Российской Федерации 2008;(3):42-44)

13. Patel M.R., Mahaffey K.W., Garg J. et al ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-91.

14. Granger C.B., Alexander J.H., McMurray J.J. et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365(11):981-92.

15. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.

16. Miller C.S., Grandi S.M., Shimony A. et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012;110(3):453-60.

17. Sulimov VA, Golitsyn SP, Panchenko, EP, et al. Diagnosis and treatment of atrial fibrillation, 2012. RCS, RSSA and ACVS Recommendations. Issue 2. Available at: http://scardio.ru/content/Guidelines/Rekomen- dations_fibrillyacia_predserdii_2012.pdf. Date of access: 28.06.2013. Russian (Сулимов В.А., Голицын С.П., Панченко Е.П., и др. Диагностика и лечение фибрилляции предсердий 2012. Рекомендации РКО, ВНОА и АССХ. Выпуск 2. Доступно на: http://scardio.ru/content/Guidelines/Rekomendations_fibrillyacia_predserdii_2012.pdf. Дата доступа: 28.06.2013).

18. Davidson T., Husberg M., Janzon M. et al. Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden. Eur Heart J 2013;34(3):177-83.

19. Shah S.V., Gage B.F. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011;123(22):2562-70.

20. Pletscher M., Plessow R., Eichler K., Wieser S. Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland. Swiss Med Wkly 2013;143:w13732.

21. Wouters H., Thijs V., Annemans L. Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium. J Med Econ 2013;16(3): 407-14.

22. González-Juanatey J.R., Álvarez-Sabin J., Lobos J.M. et al. Cost-effectiveness of dabigatran for stroke prevention in nonvalvular atrial fibrillation in Spain. Rev Esp Cardiol (Engl Ed) 2012;65(10): 901-10.

23. Adcock A.K., Lee-Iannotti J.K., Aguilar M.I. et al. Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic. Neurologist 2012;18(2): 102-7.

24. Pan F., Hernandez L., Ward A. Cost-effectiveness of stroke treatments and secondary preventions. Expert Opin Pharmacother 2012; 13(12):1751-60.

25. McKeage K. Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Pharmacoeconomics 2012;30(9):841-55.

26. Kamel H., Johnston S.C., Easton J.D., Kim A.S. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke 2012;43(3):881-3.

27. You J.H., Tsui K.K., Wong R.S., Cheng G. Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. PLoS One 2012;7(6):e39640.

28. Atay J.K., Fiumara K., Piazza G. et al Hospital budget implications of substituting dabigatran for warfarin in an anticoagulation service. Clin Appl Thromb Hemost 2012;18(2):181-4.

29. Belousov J.B., Mareev V. JU, Javelov I.S., etc. the Pharmacoeconomic analysis of efficiency of a dabigatran etexilate at patients with nonvalvular atrial fibrillation. Kardiologiia 2012; (1): 44-51. Russian (Белоусов Ю.Б., Мареев В.Ю., Явелов И.С. и др. Фармакоэкономический анализ эффективности дабигатрана этексилата у пациентов с неклапанной фибрилляцией предсердий. Кардиология 2012; (1): 44-51).

30. Belousov J.B., Mareev V. JU, Javelov I.S., Belousov D.JU. The clinico-economic analysis of efficacy of a dabigatran etexilate in comparison with warfarin in aspect of preventive maintenance of cardiovascular complications at patients with nonvalvular atrial fibrillation. Rational Pharmacother Card 2012; (1): 37-44. Russian (Белоусов Ю.Б., Мареев В.Ю., Явелов И.С., Белоусов Д.Ю. Клинико-экономический анализ эффективности дабигатрана этексилата в сравнении с варфарином в аспекте профилактики сердечно-сосудистых осложнений у пациентов с неклапанной фибрилляцией предсердий. Рациональная Фармакотерапия в Кардиологии 2012; (1): 37-44)

31. Zatejshchikov D.A., Isaeva M. JU. Questions of the organisation of treatment by anticoagulants. Clinical Practice 2012; (3): 51-62. Russian (Затейщиков Д.А., Исаева М.Ю. Вопросы организации лечения антикоагулянтами. Клиническая Практика 2012; (3): 51-62)

32. Nagarakanti R., Ezekowitz M.D., Oldgren J. et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011;123(2):131-6.

33. Rebrova O.Ju. Statistical analysis of the medical data. Application of a package of applied programs STATISTICA. Мoscow: Media Sphera; 2002. Russian (Реброва. О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.: Медиа Сфера; 2002).

34. Fletcher Р, Wagner E. Clinical epidemiology. Evidence based medicine principles. Мoscow: Media Sphere; 1998. Russian (Флетчер Р., Вагнер Э. Клиническая эпидемиология. Основы доказательной медицины. М.: Медиа Сфера; 1998).

35. Ansell J., Hirsh J., Poller L. et al The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:204S-233S.

36. Taggar J.S., Lip G.Y. Anticoagulation in atrial fibrillation: the trials and tribulations of keeping within therapeutic range. Curr Med Res Opin 2008;24:1455-8.

37. Hirsh J., Guyatt G., Albers G.W. et al Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(Suppl. 6):110S-112S.

38. Connolly S.J., Pogue J., Eikelboom J., et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029-37

39. Suman-Horduna I., Roy D., Frasure-Smith N. et al AF-CHF Trial Investigators. Quality of life and func- tional capacity in patients with atrial fibrillation and congestive heart failure. J Am Coll Cardiol 2013;61(4):455-60.

40. Henrard V., Ducharme A., Khairy P. et al for the AF-CHF investigators. Cardiac remodeling with rhythm versus rate control strategies for atrial fibrillation in patients with heart failure: Insights from the AFCHF echocardiographic sub-study. Int J Cardiol 2011. Epub ahead of print

41. Simantirakis E.N., Koutalas E.P., Vardas P.E. Arrhythmia-induced cardiomyopathies: the riddle of the chicken and the egg still unanswered? Europace 2012;14(4):466-73.

42. Lee S., Mullin R., Blazawski J., Coleman C.I. Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. PLoS One 2012;7(10):e47473.

43. Stangier J., Rathgen K., Stahle H. et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharma- col 2007;64:292-303

44. Di Nisio M., Middeldorp S., Buller H.R. Direct thrombin inhibitors. N Engl J Med 2005;353:1028-1040

45. Vorchheimer D.A., Lee J., Muller S. et al Dabigatran versus Standard Antithrombotic Therapy for New Onset Nonvalvular Atrial Fibrillation: Impact on Hospital Length of Stay. J Am Coll Cardiol 2013;61(10S): 10-13.


Review

For citation:


Kuvshinova L.E., Furman N.V., Dolotovskaya P.V., Dovgalevsky Y.P. COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE. Rational Pharmacotherapy in Cardiology. 2013;9(4):398-403. (In Russ.) https://doi.org/10.20996/1819-6446-2013-9-4-398-403

Views: 1091


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)